Abstract 387P
Background
PD-1/PD-L1 inhibitor plus chemotherapy have shown tolerability and significant clinical benefits in pts with advanced TNBC. Antiangiogenic agent could remodel tumor blood vessels and increase the response to immune-checkpoint inhibitors (ICIs). AK105, an anti-PD-1 antibody, can effectively prevents PD-1 from binding to PD-L1 and PD-L2, and avoid immune evasion of tumor cells. Anlotinib is a novel antiangiogenic, multi-target tyrosine kinase inhibitor. This investigator initiated trial aims to investigate the efficacy and safety of AK105, anlotinib combined with nab-P as a first-line therapy in pts with advanced TNBC.
Methods
In this multicenter, prospective, single arm, phase 2 study, eligible pts were female aged 18-75 years, with ECOG PS 0-1, who had locally advanced or recurrent/metastatic triple-negative breast cancer. Eligible pts were treated with intravenous AK105 (200 mg on d1), oral anlotinib (12 mg once daily on d1-d14) and intravenous nab-P (125 mg/m2 on d1 and d8). The triplet combination regimen repeated every 21 days until disease progression, death or intolerable toxicity. The primary endpoint is ORR, and the secondary endpoints are DCR, PFS, OS and safety.
Results
From July 2022 to March 2024, 33 patients have been enrolled in this study. Median follow-up was 6.54 months (95% CI 2.68-11.43). Of all the patients whose efficacy could be evaluated (26/33), 1 (3.85%) patient achieved CR; 20 (76.92%), 4 (15.38%) and 1 (3.85%) patients got PR, SD and PD, respectively. ORR was 80.77 % (95% CI 60.65-93.45) and DCR was 96.15% (95% CI 80.36-99.90). The overall mPFS was 11.14 months (95% CI 8.34-18.04), the mOS have not reached. The most common AEs were grade 1 or 2. The grade 3 AEs (incidence ≥ 10%) included were neutropenia (33.33%), leukopenia (12.12%) and elevated AST (12.12%). There were two case of grade 4 neutropenia and one case of grade 4 hypertriglyceridemia. One death (from hepatitis) was considered by the investigators to be related to the trial regimen.
Conclusions
The combination of AK105, anlotinib and nab-P showed better treatment response and tolerable toxicity in the treatment of first-line patients with TNBC.
Clinical trial identification
NCT05244993.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chiatai Tianqing.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
533P - First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
Presenter: debora basile
Session: Poster session 15
534P - Second-line treatment in older patients with metastatic colorectal cancer: The ELECTRA study
Presenter: Alessia Cordua
Session: Poster session 15
535P - Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience
Presenter: Alessandra Boccaccino
Session: Poster session 15
536P - A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: Long-term results of JCOG0603
Presenter: Yukihide Kanemitsu
Session: Poster session 15
537P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 15
538P - Combined hepatectomy with complete cytoreduction (CCS) and hyperthermic intraperitoneal chemotherapy (HIPEC) vs. HIPEC alone for metastatic colorectal cancer: A systematic review and meta-analysis
Presenter: Gabriele Lech
Session: Poster session 15
540P - Early treatment discontinuation (ETD) in dMMR/MSI-H metastastic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)
Presenter: Julien Taieb
Session: Poster session 15
541P - Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Presenter: Thierry André
Session: Poster session 15